F G Falkner

Summary

Affiliation: Baxter Healthcare Corporation
Country: USA

Publications

  1. pmc Quantitation of viral DNA by real-time PCR applying duplex amplification, internal standardization, and two-color fluorescence detection
    F Gruber
    Hyland-Immuno Division, Biomedical Research Center, Baxter, A-2304 Orth-Donau, Austria
    Appl Environ Microbiol 67:2837-9. 2001
  2. pmc Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever
    Birgit Schäfer
    Department of Virology, Baxter BioScience, Biomedical Research Center, Orth Donau, Austria
    PLoS ONE 6:e24505. 2011
  3. pmc Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity
    Annett Hessel
    Department of Virology, Baxter BioScience, Biomedical Research Center, Orth Donau, Austria
    PLoS ONE 6:e16247. 2011
  4. pmc A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations
    Annett Hessel
    R and D Vaccines, Biomedical Research Center, Baxter BioScience, Orth Donau, Austria
    PLoS ONE 5:e12217. 2010
  5. ncbi request reprint Vaccinia viral/retroviral chimeric vectors
    F G Falkner
    Baxter Vaccine AG, Biomedical Research Center, Uferstrasse 15, A 2304 Orth Donau, Austria
    Curr Gene Ther 4:417-26. 2004
  6. pmc Retroviral vectors produced in the cytoplasmic vaccinia virus system transduce intron-containing genes
    C Konetschny
    Baxter BioScience Vaccine AG Biomedical Research Center, A 2304 Orth Donau, Austria
    J Virol 76:1236-43. 2002
  7. ncbi request reprint Defective vaccinia virus as a biologically safe tool for the overproduction of recombinant human secretory proteins
    M Himly
    Baxter Immuno AG Biomedical Research Center, Uferstrasse 15, Orth Donau, A 2304, Austria
    Protein Expr Purif 14:317-26. 1998
  8. ncbi request reprint The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection
    S Coulibaly
    Baxter Vaccine AG, Biomedical Research Center, Uferstrasse 15, A 2304 Orth Donau, Austria
    Virology 341:91-101. 2005
  9. pmc Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara
    B T Ober
    Biomedical Research Center, Baxter BioScience Vaccine AG, A 2304 Orth Donau, Austria
    J Virol 76:7713-23. 2002
  10. ncbi request reprint The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses
    G Antoine
    Biomedical Research Center, Hyland Immuno, Orth Donau, Austria
    Virology 244:365-96. 1998

Collaborators

  • F Dorner
  • Thomas R Kreil
  • Brian A Crowe
  • P Noel Barrett
  • F Scheiflinger
  • M Himly
  • M Schmidt
  • U Fischer
  • Annett Hessel
  • Sogue Coulibaly
  • Georg W Holzer
  • Michael Schwendinger
  • S Coulibaly
  • Birgit Schäfer
  • Helga Savidis-Dacho
  • M Gerencer
  • B T Ober
  • C Konetschny
  • F Gruber
  • Klaus K Orlinger
  • Marie Luise Zips
  • Hartmut J Ehrlich
  • Alexandra Joachimsthaler
  • Astrid Kerschbaum
  • Nicolas Sabarth
  • Daniela Fritz
  • Otfried Kistner
  • Walter Wodal
  • G Antoine
  • K Schmid
  • J Mayrhofer
  • V Wieser
  • G W Holzer
  • H Savidis-Dacho
  • P Bruhl
  • W Gritschenberger

Detail Information

Publications10

  1. pmc Quantitation of viral DNA by real-time PCR applying duplex amplification, internal standardization, and two-color fluorescence detection
    F Gruber
    Hyland-Immuno Division, Biomedical Research Center, Baxter, A-2304 Orth-Donau, Austria
    Appl Environ Microbiol 67:2837-9. 2001
    ..The coefficient of variation was 0.29 using a run control of 2,876 copies per ml. The method reduces the risk of false-negative results, yields high precision, and is applicable for other DNA targets...
  2. pmc Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever
    Birgit Schäfer
    Department of Virology, Baxter BioScience, Biomedical Research Center, Orth Donau, Austria
    PLoS ONE 6:e24505. 2011
    ..Although, a good safety profile was historically attributed to the 17D vaccine, serious adverse events have been reported, making the development of a safer, more modern vaccine desirable...
  3. pmc Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity
    Annett Hessel
    Department of Virology, Baxter BioScience, Biomedical Research Center, Orth Donau, Austria
    PLoS ONE 6:e16247. 2011
    ..The aim of this study was to evaluate the cross-protective potential of the hemagglutinins of five H5N1 strains of divergent clades using a live attenuated modified vaccinia Ankara (MVA) vector vaccine...
  4. pmc A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations
    Annett Hessel
    R and D Vaccines, Biomedical Research Center, Baxter BioScience, Orth Donau, Austria
    PLoS ONE 5:e12217. 2010
    ..The aim of this study was to evaluate live vaccines which induce both strong humoral and cell-mediated immune responses against the novel human pandemic H1N1 influenza virus, and to show protection in a lethal animal challenge model...
  5. ncbi request reprint Vaccinia viral/retroviral chimeric vectors
    F G Falkner
    Baxter Vaccine AG, Biomedical Research Center, Uferstrasse 15, A 2304 Orth Donau, Austria
    Curr Gene Ther 4:417-26. 2004
    ..The topic of this review is the vaccinia viral / retroviral vector system and possible applications to gene therapy...
  6. pmc Retroviral vectors produced in the cytoplasmic vaccinia virus system transduce intron-containing genes
    C Konetschny
    Baxter BioScience Vaccine AG Biomedical Research Center, A 2304 Orth Donau, Austria
    J Virol 76:1236-43. 2002
    ..Thus, a relatively simple cytoplasmic system for the generation of complex retroviral vectors is described. Retroviral vectors transducing intron-containing gene cassettes may play a further role in gene therapy applications...
  7. ncbi request reprint Defective vaccinia virus as a biologically safe tool for the overproduction of recombinant human secretory proteins
    M Himly
    Baxter Immuno AG Biomedical Research Center, Uferstrasse 15, Orth Donau, A 2304, Austria
    Protein Expr Purif 14:317-26. 1998
    ....
  8. ncbi request reprint The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection
    S Coulibaly
    Baxter Vaccine AG, Biomedical Research Center, Uferstrasse 15, A 2304 Orth Donau, Austria
    Virology 341:91-101. 2005
    ..Similar to MVA, prime-boost immunizations with defective vaccinia induced robust long-term immunity, suggesting it as a promising next generation smallpox vaccine...
  9. pmc Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara
    B T Ober
    Biomedical Research Center, Baxter BioScience Vaccine AG, A 2304 Orth Donau, Austria
    J Virol 76:7713-23. 2002
    ..Therefore, a vector system was made which promises to be a valuable tool not only for immunotherapy for diseases such as cancer, human immunodeficiency virus infection, or malaria but also as a basis for a safer smallpox vaccine...
  10. ncbi request reprint The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses
    G Antoine
    Biomedical Research Center, Hyland Immuno, Orth Donau, Austria
    Virology 244:365-96. 1998
    ..Thus, the attenuated phenotype of MVA is the result of numerous mutations, particularly affecting the host interactive proteins, including the ankyrin-like genes, but also involving some structural proteins...